INDIANAPOLIS, May 18, 2016 /PRNewswire/ -- Several studies will
underscore the strength of Eli Lilly and Company's (NYSE: LLY)
diverse clinical cancer pipeline and portfolio during the
52nd Annual Meeting of the American Society of Clinical
Oncology (ASCO) in Chicago,
June 3 – 7, 2016. Presentations
include new data on abemaciclib, a CDK 4 and 6 inhibitor, as well
as: ramucirumab, a VEGF Receptor 2 antagonist; galunisertib, a TGFβ
small-molecule kinase inhibitor; and emibetuzumab, a MET
antibody.
Other data to be presented at ASCO highlight Lilly's ongoing
immuno-oncology clinical collaborations with Merck (known as MSD
outside the U.S. and Canada) in
two trials that are evaluating ramucirumab and
pemetrexed-plus-carboplatin, respectively, in combination with
Merck's pembrolizumab.
These presentations reflect Lilly's multi-faceted strategy in
developing cancer treatments – a balanced approach based on three
scientific pillars of tumor cell growth and progression: cell
signaling, tumor microenvironment and immuno-oncology. Lilly's data
at this year's ASCO meeting highlight some of the recent progress
it has made toward this strategy and touch on all three of these
scientific pillars.
"The reality is that cancer is more than 200 diseases and the
treatment of cancer needs to be aggressively approached from many
angles," said Richard Gaynor, M.D.,
senior vice president, product development and medical affairs for
Lilly Oncology. "Our oncology R&D strategy is to produce a
diverse portfolio of novel agents that attack tumor cell growth and
progression in multiple ways to improve patient outcomes."
Dr. Gaynor continued, "We are encouraged by our data at ASCO and
the progress of our pipeline toward achieving our overall goals.
We've had notable clinical advancements with abemaciclib and
olaratumab, both of which have been designated as breakthrough
therapies by the FDA. These build on necitumumab and ramucirumab,
which we are continuing to investigate in additional disease
settings and combinations. Additionally, our immuno-oncology
initiatives are increasingly producing results through
collaborations and our own internal research efforts."
Select studies, along with the times and locations of their data
sessions, are highlighted below.
Abemaciclib
- Abstract #510: Oral Abstract Session: Friday, June 3, 2016; 4:42 – 4:54 pm CDT
- MONARCH 1: Results from a phase 2 study of abemaciclib, a CDK4
and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-
breast cancer, after chemotherapy for advanced disease
- Author/Speaker: Maura N.
Dickler, M.D., Memorial Sloan Kettering Cancer Center
- Location: Hall D1
- Abstract #TPS9101: Lung Cancer—Non-Small Cell Metastatic Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- A randomized phase 2 study of abemaciclib versus docetaxel in
patients with stage IV squamous cell lung cancer (SqCLC) previously
treated with platinum-based chemotherapy
- Author/Speaker: Giorgio V.
Scagliotti, M.D., Ph.D., University of Torino
- Location: Hall A (Poster Board #423a)
Immuno-Oncology Collaborations with ramucirumab or
pemetrexed
- Abstract #3056: Developmental Therapeutics—Immunotherapy Poster
Session: Sunday, June 5, 2016; 8:00 –
11:30 am CDT
- A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in
patients (pts) with advanced gastric or gastroesophageal junction
(G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or
urothelial carcinoma (UC): Phase 1a results
- Author/Speaker: Roy S. Herbst,
M.D., Ph.D., Yale University School of
Medicine, Yale Cancer Center
- Location: Hall A (Poster Board #378)
- Abstract #9016: Lung Cancer—Non-Small Cell Metastatic Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- Pembrolizumab (pembro) plus chemotherapy as front-line therapy
for advanced NSCLC: KEYNOTE-021 cohorts A-C
- Author/Speaker: Shirish M.
Gadgeel, M.D., Karmanos Cancer Institute
- Location: Hall A (Poster Board #339)
- Poster Discussion Session: Saturday,
June 4, 2016; 3:00 – 4:15 pm
CDT Room E354b
Ramucirumab
- Abstract #TPS4145: Gastrointestinal (Noncolorectal) Cancer
Poster Session: Saturday, June 4,
2016; 8:00 – 11:30 am CDT
- A randomized, double-blind, placebo-controlled Phase III study
of ramucirumab versus placebo as second-line treatment in patients
with hepatocellular carcinoma and elevated baseline
alpha-fetoprotein following first-line sorafenib (REACH-2)
- Author/Speaker: Andrew X. Zhu,
M.D., Ph.D., Massachusetts General Hospital Cancer Center
- Location: Hall A (Poster Board #130a)
- Abstract #9079: Lung Cancer—Non-Small Cell Metastatic Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- Exploratory subgroup analysis of patients (Pts) refractory to
first-line (1L) chemotherapy from REVEL, a randomized phase III
study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO)
for second-line (2L) treatment of stage IV non-small-cell lung
cancer (NSCLC)
- Author/Speaker: Martin Reck,
M.D., Ph.D., Lungen Clinic Grosshansdorf, Airway Research Center
North
- Location: Hall A (Poster Board #402)
Galunisertib
- Abstract #4070: Gastrointestinal (Noncolorectal) Cancer Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- A phase 2 study of galunisertib, a novel transforming growth
factor-beta (TGF-β) receptor I kinase inhibitor, in patients with
advanced hepatocellular carcinoma (HCC) and low serum alpha
fetoprotein (AFP)
- Author/Speaker: Sandrine J.
Faivre, M.D., Ph.D., Service d'Oncologie Médicale
- Location: Hall A (Poster Board #62)
- Abstract #4019: Gastrointestinal (Noncolorectal) Cancer Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- A phase II, double-blind study of galunisertib+gemcitabine (GG)
vs gemcitabine+placebo (GP) in patients (pts) with unresectable
pancreatic cancer (PC)
- Author/Speaker: Davide Melisi,
M.D., University of Verona
- Location: Hall A (Poster Board #11)
- Poster Discussion Session: Saturday,
June 4, 2016; 3:00 – 4:15 pm
CDT at Hall D1
Emibetuzumab
- Abstract #9070: Lung Cancer—Non-Small Cell Metastatic Poster
Session: Saturday, June 4, 2016; 8:00
– 11:30 am CDT
- A randomized, open-label, phase 2 study of emibetuzumab plus
erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with
acquired resistance to erlotinib and MET diagnostic positive (MET
Dx+) metastatic NSCLC
- Author/Speaker: D. Ross Camidge,
M.D., Ph.D., University of
Colorado
- Location: Hall A (Poster Board #393)
About Lilly Oncology
For more than fifty years, Lilly
has been dedicated to delivering life-changing medicines and
support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making
life better for all those affected by cancer around the world. To
learn more about Lilly's commitment to people with cancer, please
visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
P-LLY
Lilly Forward-Looking Statement
This press release contains "forward-looking statements" (as that
term is defined in the United
States Private Securities Litigation Reform Act of 1995)
regarding Lilly's oncology portfolio and pipeline, including
abemaciclib, emibetuzumab, galunisertib, necitumumab, olaratumab,
pemetrexed and ramucirumab. This press release reflects Lilly's
current beliefs. However, there are substantial risks and
uncertainties in the process of drug research, development, and
commercialization. Among other risks, there can be no guarantee
that these treatment options will receive regulatory approval, or,
if approved, that it will achieve intended benefits or become a
commercially successful product. For further discussion of these
and other risks and uncertainties that could cause actual results
to differ materially from Lilly's expectations, please see the
company's latest Forms 10-K and 10-Q filed with the U.S. Securities
and Exchange Commission. Except as required by law, Lilly
undertakes no duty to update forward-looking statements.
Refer to: Erin Graves;
graves_erin_elissa@lilly.com; (908) 202-6354 (media)
Philip
L. Johnson; philip_johnson_l@lilly.com; (317) 655-6874
(investors)
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/asco-data-underscore-lillys-diverse-oncology-pipeline-and-portfolio-300270869.html
SOURCE Eli Lilly and Company